Evaluation of dysfunctional high-density lipoprotein levels with myeloperoxidase/paraoxonase-1 ratio in rheumatoid arthritis.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
22
12
2020
accepted:
12
03
2021
pubmed:
24
3
2021
medline:
10
7
2021
entrez:
23
3
2021
Statut:
ppublish
Résumé
The aim of this study is to evaluate dysfunctional high-density lipoprotein cholesterol (HDL) by measuring myeloperoxidase (MPO)/paraoxonase 1 (PON1) ratio in patients with rheumatoid arthritis (RA) and to investigate the relationship between dysfunctional HDL and cardiovascular disease (CVD) in RA patients. Sixty-seven healthy individuals and 130 RA patients were included in the study. Routine lipid panels (triglyceride (TG), low-density lipoprotein cholesterol (LDL), HDL, total cholesterol (TC), PON1 and MPO levels were measured. Disease activity scores-28 (DAS28) of RA patients were calculated. Cardiological examination records of the patients were assessed to detect patients who also have CVD. There were no significant differences between RA and control groups in routine lipid profiles (P > .05 for all). MPO/PON1 ratios were significantly elevated in the RA group compared with the control group (P < .001). MPO/PON1 ratios were higher in RA patients with CVD history compared with those without CVD (P < .05). MPO/PON1 ratios were correlated with DAS28 scores (rho: 0.357, P < .001). HDL dysfunction determined by the MPO/PON1 ratio may be associated with the pathophysiology of increased CVD in RA. Thus, evaluating dysfunctional HDL levels by measuring the MPO/PON1 ratio in RA patients may allow more detailed patient follow-up, as well as the reduction of CVD events in RA patients with therapeutic agents aiming to increase the functional properties of HDL by decreasing this ratio.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study is to evaluate dysfunctional high-density lipoprotein cholesterol (HDL) by measuring myeloperoxidase (MPO)/paraoxonase 1 (PON1) ratio in patients with rheumatoid arthritis (RA) and to investigate the relationship between dysfunctional HDL and cardiovascular disease (CVD) in RA patients.
METHODS
METHODS
Sixty-seven healthy individuals and 130 RA patients were included in the study. Routine lipid panels (triglyceride (TG), low-density lipoprotein cholesterol (LDL), HDL, total cholesterol (TC), PON1 and MPO levels were measured. Disease activity scores-28 (DAS28) of RA patients were calculated. Cardiological examination records of the patients were assessed to detect patients who also have CVD.
RESULTS
RESULTS
There were no significant differences between RA and control groups in routine lipid profiles (P > .05 for all). MPO/PON1 ratios were significantly elevated in the RA group compared with the control group (P < .001). MPO/PON1 ratios were higher in RA patients with CVD history compared with those without CVD (P < .05). MPO/PON1 ratios were correlated with DAS28 scores (rho: 0.357, P < .001).
CONCLUSION
CONCLUSIONS
HDL dysfunction determined by the MPO/PON1 ratio may be associated with the pathophysiology of increased CVD in RA. Thus, evaluating dysfunctional HDL levels by measuring the MPO/PON1 ratio in RA patients may allow more detailed patient follow-up, as well as the reduction of CVD events in RA patients with therapeutic agents aiming to increase the functional properties of HDL by decreasing this ratio.
Substances chimiques
Lipoproteins, HDL
0
Triglycerides
0
Peroxidase
EC 1.11.1.7
Aryldialkylphosphatase
EC 3.1.8.1
PON1 protein, human
EC 3.1.8.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14172Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Marcucci E, Bartoloni E, Alunno A, et al. Extra-articular rheumatoid arthritis. Reumatismo. 2018;70(4):212-224.
Urman A, Taklalsingh N, Sorrento C, McFarlane IM. Inflammation beyond the joints: rheumatoid arthritis and cardiovascular disease. SciFed J Cardiol. 2018;2(3):1000019.
Bag-Ozbek A, Giles JT. Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? Curr Allergy Asthma Rep. 2015;15(2):497.
Arida A, Protogerou A, Kitas G, Sfikakis P. Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci. 2018;19(7):1890.
Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17-28.
Kim JY, Lee EY, Park JK, Song YW, Kim JR, Cho KH. Patients with rheumatoid arthritis show altered lipoprotein profiles with dysfunctional high-density lipoproteins that can exacerbate inflammatory and atherogenic process. PLoS ONE. 2016;11(10):e0164564.
Charles-Schoeman C, Meriwether D, Lee YY, Shahbazian A, Reddy ST. High levels of oxidized fatty acids in HDL are associated with impaired HDL function in patients with active rheumatoid arthritis. Clin Rheumatol. 2018;37(3):615-622.
Aviram M, Vaya J. Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. Curr Opin Lipidol. 2013;24(4):339-344.
Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res. 2009;50(suppl.):S346-S351.
Mehta NN, Li R, Krishnamoorthy P, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012;224(1):218-221.
Kotosai M, Shimada S, Kanda M, et al. Plasma HDL reduces nonesterified fatty acid hydroperoxides originating from oxidized LDL: a mechanism for its antioxidant ability. Lipids. 2013;48(6):569-578.
Haraguchi Y, Toh R, Hasokawa M, et al. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. Atherosclerosis. 2014;234(2):288-294.
Neşelioğlu S, Pekcan G, Gök G, Yurt EF, Erel O. Investigation of dysfunctional HDL using myeloperoxidase/paraoxonase ratio in lymphoma. Harran Üniversitesi Tıp Fakültesi Dergisi. 2019;16(2):358-364.
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.
Sarioglu N, Bilen C, Cevik C, Gencer N. Paraoxonase activity and phenotype distribution in patients with chronic obstructive pulmonary disease. Eurasian J Med. 2020;52(2):161-165.
Curtis JR, Yang S, Singh JA, et al. Is rheumatoid arthritis a cardiovascular risk-equivalent to diabetes mellitus? Arthritis Care Res. 2018;70(11):1694-1699.
Crowson CS, Therneau TM, Davis JM III, Roger VL, Matteson EL, Gabriel SE. Brief report: accelerated aging influences cardiovascular disease risk in rheumatoid arthritis. Arthritis Rheum. 2013;65(10):2562-2566.
Meyer PW, Anderson R, Ker JA, Ally MT. Rheumatoid arthritis and risk of cardiovascular disease. Cardiovasc J Afr. 2018;29(5):317-321.
Gantait K, Barman H, Gantait I. A comparative study on different fraction of lipid and das28 score in patients of early arthritis. J West Bengal Univ Health Sci. 2020;1(1):41-46.
Rosenson RS, Brewer HB, Ansell B, et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013;128(11):1256-1267.
Manninen S, Lankinen M, Erkkilä A, et al. The effect of intakes of fish and Camelina sativa oil on atherogenic and anti-atherogenic functions of LDL and HDL particles: a randomized controlled trial. Atherosclerosis. 2019;281:56-61.
Alén JC, Lavín BA, Aurrecoechea E, Ruiz ARG, Taboada VM, Gerique JG. TNF inhibitors exert a “hidden” beneficial effect in the cardiovascular lipoprotein profile of RA patients. Research square. 2020. https://doi.org/10.21203/rs.3.rs-44189/v1
Kim SY, Yu M, Morin EE, Kang J, Kaplan MJ, Schwendeman A. High-density lipoprotein in lupus: disease biomarkers and potential therapeutic strategy. Arthritis Rheumatol. 2020;72(1):20-30.
Shoeib SA, Tawfeek AR, Fathy WM, Nouh MZ, El-Kholy AM. Paraoxonase-1 enzyme activity in rheumatoid arthritis patients: association with carotid intima-media thickness? Menoufia Med J. 2020;33(1):82.
Gaál K, Tarr T, Lőrincz H, et al. High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus. Lipids Health Dis. 2016;15(1):60.
Greco D, Gualtierotti R, Agosti P, et al. Anti-atherogenic modification of serum lipoprotein function in patients with rheumatoid arthritis after tocilizumab treatment, a pilot study. J Clin Med. 2020;9(7):2157.
Bae SC, Lee YH. Associations between paraoxonase-1 and systemic lupus erythematosus. Lupus. 2019;28(13):1571-1576.
Parada-Turska J, Wójcicka G, Beltowski J. Paraoxonase 1 phenotype and protein n-homocysteinylation in patients with rheumatoid arthritis: implications for cardiovascular disease. Antioxidants. 2020;9(9):899.
Kunutsor SK, Bakker SJL, James RW, Dullaart RPF. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: the PREVEND study and meta-analysis of prospective population studies. Atherosclerosis. 2016;245:143-154.
Shevchuk S, Seheda Y, Galyutina O, Masik N, Shevchuk O. Serum paraoxonase activity in patients with rheumatoid arthritis, its relationship with the clinical course and cardiovascular compications. Regul Mech Biosyst. 2018;9(1):90-94.
Aratani Y. Myeloperoxidase: its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys. 2018;640:47-52.
Wang W, Jian Z, Guo J, Ning X. Increased levels of serum myeloperoxidase in patients with active rheumatoid arthritis. Life Sci. 2014;117(1):19-23.
Rosenson RS, Brewer HB, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13(1):48-60.
D'Agostino RB, Pencina MJ, Massaro JM, Coady S. Cardiovascular disease risk assessment: insights from Framingham. Global Heart. 2013;8(1):11-23.
Hollan I, Ronda N, Dessein P, et al. Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2020;6(2):104-114.
Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol. 2020;16(7):361-379.
Hafiane A, Genest J. High density lipoproteins: measurement techniques and potential biomarkers of cardiovascular risk. BBA Clin. 2015;3:175-188.
Charles-Schoeman C, Yin Lee Y, Shahbazian A, et al. Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis Rheumatol. 2017;69(1):46-57.